Reports

Ideas That Generate Results

Erythropoietin Market Forecast to 2015

Erythropoietin Market Forecast to 2015

Format :  Adobe Reader (PDF) Upto 24 hour delivery
Publish Date : Jun, 2012| No. of Pages : 34

Share |
Please make your selection :
Electronic Access - Single User License
US$ 400.00
CD-ROM Mail Delivery
US$ 500.00
Hard Copy Mail Delivery
US$ 500.00
Electronic Access - Multi-User License
US$ 800.00

In the biopharmaceutical industry, protein-based therapies have become one of the most effective clinical methods to treat a wide spectrum of diseases, ranging from cancer to metabolic disorders. According to our new research report, the market for Erythropoietin (EPO), a glycoprotein hormone responsible for the regulation of red blood cell production, represents one of the significant segments of the protein therapeutics market. The second-generation EPO, also called darbepoetin, is gaining market share as it allows patients to administer dose at much lower frequency.

The clinical application of EPO lies in the treatment of anemia resulting from chronic renal failure or cancer chemotherapy. The report, “Erythropoietin Market Forecast to 2015”, finds that three types of EPO are commercially available at present, and the US represents the world’s largest market for EPO. Our comprehensive research work also studied the global protein therapeutics market, which is estimated to cross the US$ 143 Billion-mark by 2015-end as new products, especially monoclonal antibodies in the advanced clinical phase, may enter the market.

Our report prudently analyzes the Erythropoietin market, covers the competitive landscape, and evaluates its current and future size. The study of key geographical markets and recent developments have been included in the in-depth research. This way, the extensive study will prove to be a complete source of knowledge and analysis for clients and potential investors.

Not able to find data you are looking for? Ask our Research Analyst.

media citation

get in touch

Please fill-in the information below.